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Abstract 
Tramadol, a centrally acting analgesic opioid, is considered to have a low abuse potential and is devoid of side effects like 
drug dependence, liver and kidney toxicity.. The present study was conducted to assess the tramadol addiction effects on 
both liver and kidney functions among tramadol abusers. A total of 50 male individuals with a tramadol abuse problem 
were referred to psychiatric clinics in Gaza Strip, along with an age matched normal control. An informed consent was 
obtained, a questionnaire was filled, blood samples were collected, serum was separated, and tested serologically to detect 
antibodies to hepatitis A virus, the presence of hepatitis B surface antigen, and IgM antibodies to hepatitis A virus. 
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and lactate dehydrogenase 
(LDH) activities, bilirubin, creatinine, uric acid and blood urea nitrogen (BUN) levels were measured in the serum. Serum 
ALT, AST and LDH levels were significantly higher in abuser group compared to the control group.  Serum ALP, direct 
bilirubin, total bilirubin, BUN, uric acid  and creatinine levels significantly increased  in the abusers that were addicted to 
tramadol for more than 5 years. Our results point out the risk of increased hepatic and renal damage due to a long-term use 
of tramadol. Although opioids are reported to be effective in pain management, their toxic effects should be kept in mind 
during the chronic usage. In addition, measures to control the spread of tramadol abuse should be implemented. 
Keywords: Tramadol addiction, Liver toxicity, Kidney toxicity, Gaza Strip, Palestine16T. 
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1. Introduction 
Tramadol (Tramal TM) is a centrally acting synthetic 
opioid analgesic agent, used parenterally and orally for 
the treatment of moderate to severe pain. The mechanism 
of its analgesic action is complex. Most reports suggest 
that the analgesic activity and other clinical effects of 
tramadol are a result of opioid and non-opioid 
mechanisms. Tramadol binds to the μ-opioid receptor, 
although much more weakly than morphine. It also 
inhibits the  neuronal reuptake of norepinephrine and 
serotonin as do the antidepressant drugs such as 
amitriptyline and desimpramine (Raffa et al., 1992; Raffa, 
1996; Dayer et al., 1997; More et al., 1999; Grond and 
Sablotzki, 2004; Gillman, 2005).  
Tramadol has a high oral bioavailability in the range of 
70- 80%. Peak blood levels are reached in about 2 hours 
after an oral dose. It is metabolized in the liver by the 
cytochrome p450 and by-products are excreted through 
the kidney. Its biotransformation occurs in the liver and 
results in O-desmethyl-tramadol, which itself is an active 
substance and 2  to 4 times more potent than tramadol 
(Subrahmanyam et al., 2001; Wu et al., 2001; Tao et al., 
2002; Wu et al., 2002; Halling et al., 2008). Further, 
biotransformation results in inactive metabolites, which 
are excreted by kidneys (Lee et al., 1993; Matthiessen et 
al., 1998).  
Tramadol has a dose-dependent analgesic efficacy that 
lies between that of codeine and morphine, with a 
parenteral potency comparable to that of pethidine, i.e., 
about 10- 20 % of the standard morphine (Wilder-Smith 
et al., 1999; Pang  et al., 2003). A long-term of tramadol 
administration for management of pain, as well as its use 
as an acceptable alternative for persons with drug-seeking 
behavior is controversial. However, the tramadol's effects 
at a cellular level are not clearly understood (Brena and 
Sander, 1991; McCarberg and Barkin, 2001; Atici, 2005). 
The adverse effects associated with the medicine used 
in clinics constitute a serious problem for patients and 
health care providers (Asis et al., 2009). It has been 
estimated that about 10% of drugs are associated with 
severe, undesirable side effects (Hussaini and Farrington, 
2007; Shi et al., 2010). However, this number is probably 
underestimated, given that drug-induced adverse effects 
are difficult to detect due to pre-existing medical 
conditions, multiple drug usage, and lack of diagnostic 
standards (Asis et al., 2009). 
The central role of liver and kidney in detoxification 
and drug metabolism increases the risks of toxic injury. 
Almost certainly, every drug has been associated with 
hepatotoxicity due to the essential role of the liver in drug 
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metabolism (Poppers, 1980; Tolman, 1998). Metabolites 
of the drugs that are excreted from kidneys may also 
cause a cellular damage leading to a kidney dysfunction 
and may have a higher activity and/or a greater toxicity 
than the original drug (Singhal et al., 1998).  
Tramadol is considered to have a low abuse potential 
and is devoid of side effects, like drug-dependence. A 
tramadol overdose may lead to a Central Nervous System 
(CNS) depression, nausea and vomiting, tachycardia, 
seizures, coma, respiratory depression and cardiovascular 
collapse (Jones, 2005; Chandrasekaran, 2007). Very few 
fatalities have been reported so far (Pothiawala et al., 
2011). Therefore, a tramadol dosage should be adjusted 
according to the pain severity. The total daily dose should 
not exceed 400mg in adult therapeutic blood levels of 
0.1–0.8 mg/L (Clarot et al., 2003). 
Unfortunately, the unregulated access of tramadol to 
Gaza Strip leads to the misuse of the drug and this is 
considered a serious problem that may have a negative 
impact on liver and kidneys among users. A cross-
sectional prospective study was conducted to assess the 
liver and kidney functions among chronic users of 
tramadol in Gaza Strip. In addition, an investigation of the 
possible causes of tramadol abuse was attempted. 
2. Materials and Methods 
2.1. . Study Population 
The present study is analytical and descriptive. A total 
of 50 male individuals with tramadol abuse problems, 
ranging from 15 to 35 years old, were referred between 
September 2013 to June 2014 to psychiatric clinics in 
Gaza Strip. A normal control group with matching age 
and sex was also included, with the condition that they 
did not take any medication, and did not suffer from any 
chronic diseases. All the selected abusers were free of 
chronic diseases, such as diabetes mellitus, hypertension, 
heart diseases and kidney or liver failure; all had a history 
of addiction. 
The purpose and the procedures of the present study 
were explained to all participants. An informed consent 
was obtained, a questionnaire filled, and a blood sample 
was collected. Helsinki ethical committee in Gaza Strip 
approved of this study.  
2.2. Sample Collection 
Blood samples were collected into plain tubes, and 
then the specimens were transported within one hour to 
the Clinical Chemistry Laboratory of the Faculty of 
Health Sciences, Islamic University - Gaza. Blood 
samples were centrifuged at 4000 rpm for 10 minutes, 
serum was separated immediately. All blood specimens 
were tested serologically to detect antibodies to hepatitis 
C virus (HCV), the presence of  hepatitis B surface 
antigen (HbsAg), and IgM antibodies to hepatitis A virus 
(HAV) by enzyme linked immunosorbent assay (ELISA) 
(CTK Biotech Inc, San Diego). Then, biochemical tests 
were performed within two hours. 
2.3. Biochemical Analysis 
Levels of Serum enzymes Aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP) and lactate dehydrogenase (LDH) 
activities, bilirubin, creatinine, uric acid and blood urea 
nitrogen (BUN) were determined in the serum using 
(BioSystem, Barcelona) protocols. Data entry and 
analysis were done using Statistical Package for Social 
Sciences (SPSS version 20) software. Comparisons were  
made using Chi-square test and t-test. A P-value of < 0.05 
was considered indicative of a statistically significant 
difference. 
3. Results  
3.1. Description of Study Subjects  
A total of 100 specimens (50 tramadol abusers who are 
admitted to psychiatric clinics in Gaza Strip and 50, of 
matching age and sex, as control) were included in the 
study. 28 (56%) of the abusers were from the age group of 
21-25 years old, followed by the age group of 26-30 
(24%), the age group of 31-35 (12%) and the age group of 
15-20 (8%)  (Figure 1). All abusers were male. 
Figure 1. Abusers distribution by age 
Twenty-five (50%) of the patients were at the 
secondary educational level, 27 (54%) of the patients 
were single. The addiction profile for the patients showed 
that the average addiction period was 4 years (ranging 
from 0.5 to 15 years). Most of the patients, 33, (66%)  
were addicted to a tramadol dose of more than 500 mg 
and 17 (34%) were addicted to a tramadol dose of less 
than 500 mg  (Table 1) with an average intake of 5 times 
per day. 48 (96%) of the patients were smokers. Patients 
selected were free of any abnormalities that may 
introduce abnormal results in liver and kidney function 
tests; any patient with positive HAV, HBV, or HCV tests 
was excluded. None of the patients had a chronic disease 
such as diabetes, hypertension, heart, and kidney or liver 
diseases. 
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Table 1. Tramadol dose intake among patients (N=50) 
3.2. Liver Function Tests 
Liver toxicity does not solely occur by drug 
metabolites that accumulate due to over dosage (Singhal 
et al., 1998); it can also occur through viral infection. In 
the present study, all patients were tested for hepatitis 
viruses (HAV, HBV, and HCV) and only those with 
negative results were included in the study.  
With regard to liver function tests, ALT results were 
significantly higher at p-value of less than 0.05 in 
tramadol abusers (72%) against the control group (0%) 
(Figure 2A).   
About 50% of the tramadol abusers showed abnormal 
AST and LDH results in comparison with the control 
group that scored only 16% (Figures 2B and 2D). ALP, 
direct billirubin, and total bilirubin results showed no 
significant difference between the two groups. When the 
addiction period was considered in comparing the results, 
it was found that 4% of the "more than 5 years tramadol 
abusers" showed an abnormal result against a 100% 
normal result among the control group (Figure 2C). 
3.3. Kidney Function Tests 
During the vital role of kidney in blood clearance from 
toxic compounds, some of these compounds, such as drug 
metabolites, may cause a cellular damage, leading to a 
kidney dysfunction (Singhal et al., 1998). 
Kidney function was evaluated among the tramadol 
addicts and the results showed that a low percentage of 
the abusers (ranging from 6% -10%) had abnormal BUN 
and Uric acid value. Those patients were categorized as 
chronic addicts for more than five years (Figure 3 A and 
B); this indicates that the long-term tramadol addiction 
may cause kidney injury. The creatinine levels showed no 




Figure 2. Liver enzymes results in patients and control serum. At P < 0.05 patients showed significant higher ALT results (A) , AST 
results (B). ALP, Direct bilirubin and Total bilirubin and bilirubin was only elevated in patients addicted to tramadol more than 5 years 
(C). Data significantly showed high levels of LDH among patients at P < 0.05 (D). 
  
Figure 3. Kidney function tests results in patients and control serum. At P < 0.05 patients with long term of addiction had abnormal BUN 
results (A), uric acid results (B).
   
 Daily dose Frequency Percent  
Less than 500 mg 17 34.0 
500-1000 mg 13 26.0 
1001-1500 mg 7 14.0 
1501-2000 mg 5 10.0 
More than 2000 mg 8 16.0 
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4. Discussion  
Tramadol overdosing has been one of the most 
frequent causes of drug poisoning in the recent years, 
especially in young adult males with a history of 
substance abuse and mental disorders (Shadina et al., 
2008). When overdosed, it is, as believed, associated with 
significant morbidity and mortality (Jones, 2005; and 
Chandrasekaran, 2007). The present is the first study that 
attempts to assess the effects of tramadol addiction on 
liver and kidney functions among the chronic users of 
tramadol in young adults of Gaza Strip.  
The hepatic function in drug metabolism involves 
converting drugs and other compounds into products that 
are more easily excreted (Coughtrie et al., 1989; Milne et 
al., 1997; Tolman, 1998). Metabolites may have a higher 
activity and/ or a greater toxicity than the original drug. 
These metabolites, excreted via kidneys, may also cause a 
cellular damage and, thus, a kidney dysfunction (Singhal 
et al., 1998). The liver and kidney are responsible for the 
tramadol metabolism and excretion and the high risk of 
hepatotoxicity and nephrotoxicity (Wu et al., 2001; 
Jansen, 2005). 
In the present study, tramadol abusers' personal data 
showed that about 56% of the abusers were 21 to 25 years 
old, and 50% did not go to college. This age is 
particularly critical, especially with the difficult 
socioeconomic status along with a life of hardship and 
unemployment. Another key factor that could contribute 
to the use of tramadol and other drugs by young adults is 
the absence of awareness of the hazardous effects of such 
drugs and also to the relatively easy accessibility. This is 
in agreement with a study performed in Iran, showing that 
the majority of people seeking tramadol from pharmacies 
are adolescents/ young adults taking tramadol orally, with 
the criteria for drug addiction (Zabihi et al., 2011). Most 
of patients, 33 (66%),  were addicted to a tramadol dose 
of more than 500mg by means of opioid overdose 
according to previous published data that considered the 
total daily dose should not exceed 400mg for adult 
therapeutic blood levels of 0.1–0.8mg/L (Clarot et al., 
2003) 
The liver function was evaluated through measuring 
Aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP) and 
lactate dehydrogenase (LDH) activities and serum 
bilirubin. The results showed a significantly higher ALT 
result among tramadol abusers compared with the control 
group. About 50% of the tramadol abusers (> 5 years 
abuse) showed abnormal AST and LDH results; and this 
is in agreement with the findings of a study carried out by 
Panchenko et al. (1999). A significant increase in the 
level of ALT and AST was reported among rats that 
received 40 and 80 mg/kg of tramadol with a pronounced 
effect caused by the large dose and the duration of drug 
administration (El-Gaafarawi, 2006). Those findings were 
similar to previous studies conducted on long-term 
tramadol treated mice (Borzelleca et al., 1994; Aitic et al., 
2005; Elyazji et al., 2013; Rukhshanda et al., 2014). 
ALP and billirubin results showed no significant 
difference between tramadol abuser and control groups 
except for the chronic abusers (more than 5 years) who 
showed abnormal levels. This indicates that the long-term 
use of tramadol intake is more harmful to liver and causes 
a serious cellular toxicity and a liver failure. Previous 
histopathological studies indicated the necrosis, 
vacuolization, central vein dilation, hemorrhage, cytolysis 
and complete cell membrane degeneration in hepatocytes 
in tramadol long-term treated mice (Aitic et al., 2005; 
Rukhshanda et al., 2014).  
Moreover, the results of the kidney function tests 
showed an increase in BUN, uric acid and creatinine 
levels in samples obtained from the-more-than-5-years 
tramadol abuser. This suggests that the long-term use of 
tramadol has negative impacts on kidney functionality. 
This result is in accordance with Aitic et al. (2005) who 
reported an increase in BUN and creatinine levels in rats 
with long-term tramadol receiving; others studies reached 
similar results (Borzelleca et al., 1994; Aitic et al., 2005; 
Elyazji et  al., 2013; Rukhshanda et al., 2014). 
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